(redirected from Chronic thromboembolic pulmonary hypertension)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy
  • noun

Synonyms for hypertension

a common disorder in which blood pressure remains abnormally high (a reading of 140/90 mm Hg or greater)

References in periodicals archive ?
Findings on Submillimeter MDCT Are Predictive of Operability in Chronic Thromboembolic Pulmonary Hypertension.
State-of-the art imaging techniques in chronic thromboembolic pulmonary hypertension.
Thrombophilic factors in chronic thromboembolic pulmonary hypertension.
Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension.
Characterization of Chinese Patients With Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Baseline Characteristics from the PATENT-1 and CHEST-1 Studies and Comparison With Other Studies
Health Outcome Assessment in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Patients Treated with Riociguat: 2-Year Results from the CHEST-2 Long Term Extension Study
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): 1-Year Results from the CHEST-2 Long-term Extension Study
The results of the CHEST-2 trial support the positive data of the pivotal CHEST-1 trial, showing long-term safety and sustained clinical benefits in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
The Committee also voted 11 to 0 that riociguat should be approved for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) of WHO Group 4.
We are pleased that multiple new data sets from our riociguat clinical development program in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension were accepted for presentation during the ATS International Conference," said Pamela A.
Food and Drug Administration (FDA) seeking approval for riociguat, an investigational compound for the treatment of pulmonary arterial hypertension (PAH) and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH.
23, 2012 /PRNewswire/ -- Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery.
In addition to PAH, riociguat is currently under investigation for other types of pulmonary hypertension, including chronic thromboembolic pulmonary hypertension (CTEPH).
Data from two pivotal, Phase III trials researching riociguat in patients with for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) will be presented as late-breaking abstracts in oral presentation sessions.
Guidance is provided for identifying and treating people with massive and submassive pulmonary embolism (dangerous blockage in veins in the lungs), iliofemoral deep vein thrombosis (blockage in the main vein of the pelvis and leg), and chronic thromboembolic pulmonary hypertension (serious high blood pressure in the lungs caused by blood clots).
Full browser ?